AbbVie
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.22 | 29 |
| neurology | ×1.50 | 5 |
| immunology | ×0.70 | 4 |
| gastroenterology | ×1.50 | 4 |
| dermatology | ×1.50 | 3 |
| ophthalmology | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.49 | 12 |
| phase 1 | ×1.10 | 10 |
| phase 2 | ×1.50 | 9 |
| phase 3 | ×0.92 | 9 |
| preclinical | ×1.50 | 7 |
| discovery | ×0.87 | 4 |
Strategy profile
Based on 15 disclosed transactions, AbbVie concentrates its licensing activity in Oncology, Gastroenterology, and Immunology. AbbVie pays a 1.36x premium over market median, with the strongest premiums in Neurology (1.50x). Their most common deal structure is License, with an average disclosed value of $1.4B. Most recent activity: 2025.
Premium by therapeutic area
How AbbVie pays relative to peer medians in each TA
Pipeline coverage & gaps
AbbVie has disclosed activity in 6 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 6 | $251M | $1.6B |
| Acquisition | 4 | $988M | $988M |
| Collaboration | 4 | $49M | $1.5B |
| Option | 1 | $65M | $2.0B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | In vivo CAR-T platform | Capstan Therapeutics | Lupus, Myasthenia Gravis | preclinical | $2.1B | $2.1B |
| 2025 | B7-H4-201 | MacroGenics | Cholangiocarcinoma | preclinical | $53M | $481M |
| 2025 | Masked T-cell engagers program | Xilio Therapeutics | solid tumors | unknown | — | $2.1B |
| 2025 | Gubra obesity peptide | Gubra | Obesity | preclinical | $350M | $2.2B |
| 2024 | inflammation | OSE Immunotherapeutics | inflammation | preclinical | $48M | $713M |
| 2024 | lung_nsclc | Kelun-Biotech | lung_nsclc | phase_2 | $200M | $1.4B |
| 2024 | alzheimers | Aliada Therapeutics | alzheimers | phase_1 | $1.4B | $1.4B |
| 2024 | psoriasis | Nimble Therapeutics | psoriasis | preclinical | $200M | $200M |
| 2024 | ISB 2001 | Ichnos Glenmark Innovation | Relapsed/refractory multiple myeloma | phase_1 | $700M | $1.9B |
| 2024 | ibd | Celsius Therapeutics | ibd | phase_1 | $250M | $250M |
| 2024 | HBM7008 | Harbour BioMed | Breast, Ovarian, Endometrial | phase_1 | $50M | $1.8B |
| 2024 | solid_tumors | EvolveImmune Therapeutics | solid_tumors | preclinical | $65M | $1.4B |
| 2024 | liver_disease | Medincell | liver_disease | preclinical | $35M | $1.9B |
| 2024 | Gilgamesh psychiatric/psychedelic-inspired agents (multi-asset) | Gilgamesh | psychiatric / neuropsychiatry | preclinical | $65M | $2.0B |
| 2024 | FG-M701 | FutureGen Biopharmaceutical | Ulcerative Colitis, Crohn's Disease | preclinical | $150M | $1.7B |
How this is computed
For each AbbVie deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 51 disclosed deal premiums vs. peer medians. Raw premium 1.365, clamped to [0.7, 1.5].